Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23727040 | 1.00 | HPGD (0.58) | HPGDRECQLKMT2AALDH1A1MEN1 | |
| SCHEMBL407899 | 0.94 | HPGD (0.56) | HPGDRECQLKMT2AALDH1A1MAPT | |
| SCHEMBL968401 | 0.89 | MEN1 (0.56) | HPGDRECQLKMT2AALDH1A1MEN1 | |
| SCHEMBL3730650 | 0.89 | HPGD (0.51) | HPGDRECQLKMT2AALDH1A1EPHX1 | |
| SCHEMBL442932 | 0.89 | MEN1 (0.56) | HPGDRECQLKMT2AALDH1A1MEN1 | |
| SCHEMBL1249710 | 0.89 | MEN1 (0.56) | HPGDRECQLKMT2AALDH1A1MEN1 | |
| SCHEMBL389962 | 0.86 | HPGD (0.54) | HPGDRECQLKMT2AALDH1A1MEN1 | |
| SCHEMBL894559 | 0.86 | HPGD (0.54) | HPGDRECQLKMT2AALDH1A1MEN1 | |
| SCHEMBL586312 | 0.86 | HPGD (0.54) | HPGDRECQLKMT2AALDH1A1MEN1 | |
| SCHEMBL4842173 | 0.86 | HPGD (0.48) | HPGDRECQLKMT2AALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2024-07-04 | — | — | US | disclosed |
| CN-116034107-A | Quinuclidinone analogs as anticancer agents | 新波制药有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4100407-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | Newave Pharmaceutical Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022204109-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2021158948-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2017024996-A1 | HYDROXY AMIDINE DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | 江苏恒瑞医药股份有限公司 | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089530-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, CNKSR1, NQO1 | HPGD 1471/4885RECQL 72/4885KMT2A 212/4885 |
| US-20240217964-A1 | QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS | NQO2, PRMT1, PRMT7 | HPGD 1500/4885RECQL 28/4885KMT2A 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.